Chronic graft-versus-host disease (GVHD) is a systemic syndrome that presents with variable, often extensive, clinical features, which mimic autoimmune disease and other immunologic disorders, such as systemic sclerosis, lupus erythematosus, or Sjögren syndrome.¹ Chronic GVHD remains an important limiting factor for the success of allogeneic hematopoietic stem-cell transplantation (allo-HSCT), mostly because of associated complications, namely infections and organ failure. Thus, chronic GVHD is the leading cause of late nonrelapse mortality (NRM) and morbidity after allo-HSCT. Allo-HSCT using granulocyte colony-stimulating factor–mobilized peripheral blood stem cells (PBSC) from HLA-matched unrelated or HLA-mismatched donors, which are well-identified risk factors for chronic GVHD,^2,3 is on the rise.⁴ Data from the Center for International Blood and Marrow Transplant Research showed increased incidence of chronic GVHD⁵ in these types of transplant.

中文翻译：

---

抗胸腺球蛋白对异基因造血干细胞移植后移植物抗宿主病的预防作用

慢性移植物抗宿主病（GVHD）是一种系统性综合征，具有多种多样的，通常是广泛的临床特征，可模仿自身免疫性疾病和其他免疫性疾病，例如系统性硬化症，红斑狼疮或Sjögren综合征。¹慢性GVHD仍然是同种异体造血干细胞移植（allo-HSCT）成功的重要限制因素，主要是由于相关的并发症，即感染和器官衰竭。因此，慢性GVHD是异基因造血干细胞移植术后晚期非复发死亡率（NRM）和发病率的主要原因。使用来自HLA匹配的无关或HLA不匹配的供体的粒细胞集落刺激因子动员的外周血干细胞（PBSC）进行的Allo-HSCT，这是公认的慢性GVHD危险因素，^2,3在上升。⁴国际血液和骨髓移植研究中心的数据显示，这些类型的移植物中慢性GVHD ^5的发生率增加。